Viracta Therapeutics, Inc. - VIRX EV/Sales Multiple

Public company logo of Viracta Therapeutics (VIRX)

Viracta Therapeutics is developing therapies for Epstein-Barr virus-associated lymphomas, systematically preparing its lead drug for registration. The enterprise value-to-revenue ratio reflects the market's reaction to these achievements, with serving as the final level marker. Stability is provided by a proprietary enzyme activation platform and strategic partnerships, while the implementation of "green chemistry" minimizes the toxicity of production waste.

Viracta (VIRX) Company Value to Revenue: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Viracta Therapeutics, Inc. (VIRX)

Fundamental valuation:Viracta Therapeutics Inc. (VIRX)
Mass-produced product of viracta.com

This ratio compares the total enterprise value to sales volume, excluding the impact of leverage to determine the actual market revaluation of operating flows. Analyzing the dynamics of the EV/Revenue multiple allows for stress-testing the resilience of Viracta Therapeutics (VIRX) assets, confirming that the uniqueness of the Kick & Kill platform and patent protection create a fundamental barrier against capitalization degradation.

Competitor analysis for Viracta Therapeutics

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio Ascentage Pharma Group|Company Value to Revenue Ratio CGON (CG Oncology Corp)|Enterprise Value-to-Revenue Ratio UroGen Pharma (URGN)|EV/Sales Multiple Bicara Therapeutics (BCAX)|EV/Sales Multiple PSNL (personalis.com)|Business Value to Revenue ERAS|DCTH: Company Value to Revenue|YmAbs - Enterprise Value-to-Revenue Coefficient|aurabiosciences.com (AURA) - Enterprise Value-to-Revenue Ratio|Candel Therapeutics Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Accuray Inc.|Enterprise Value-to-Revenue Multiple SELLAS Life Sciences Group SLS|EV/Sales Multiple ACTU|CTOR - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple HURA (TuHURA Biosciences, Inc.)|Business Value to Revenue TARA|FATE: Company Value to Revenue|WHWK (aadibio.com) - Company Value to Revenue Ratio|TCRX (TScan Therapeutics, Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - EV/Sales Multiple|CVM (CEL-SCI Corporation) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple OSTX|EV/Sales Multiple Radiopharm Theranostics Ltd (RADX)|EV/Sales Multiple ARTV (Artiva Biotherapeutics)|EV/Sales Multiple Adlai Nortye Ltd. ANL|Veru Inc - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Tempest Therapeutics TPST|XLO: EV/Sales Multiple|Enochian BioSciences (RENB) - EV/Sales Multiple|Company Value to Revenue MURA|Kairos Pharma Ltd - Enterprise Value to Sales Volume|EV/Sales Multiple OKUR|CytoMed Therapeutics Limited (GDTC) - Enterprise Value-to-Sales Ratio|EV/Sales Multiple CRIS (Curis, Inc.)|APLM: Company Value to Revenue Ratio|Tharimmune Corporation - EV/Sales Multiple|ADVB: Enterprise Value-to-Revenue Ratio|GNPX: EV/Sales Multiple|CLDI (Calidi Biotherapeutics Inc.) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Sunshine Biopharma, Inc.|EV/Sales Multiple xeneticbio.com|Enterprise Value-to-Revenue Ratio Salarius (SLRX)|Company Value to Revenue Purple Biotech PPBT|Enterprise Value-to-Revenue Ratio American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Enterprise Value-to-Revenue Multiple|Checkpoint Therapeutics Inc. - EV/Sales Multiple|Business Value to Revenue ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Company Value to Revenue|Ikena Oncology, Inc. - Business Value to Revenue|Company Value to Revenue NTBL|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio